Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ILC DoverILC Dover Introduces DoverDoQ™ to Advance Contained Potent Powder Transfer in Pharmaceutical ManufacturingILC Dover, an Ingersoll Rand business and global leader in containment and material handling solutions, today announced the launch of DoverDoQ™, a semi-automatic connection system designed to enable safe, reliable, and highly contained...
- The Rosen Law Firm PAAARDVARK DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the...
- Silexion Therapeutics Announces Exercise of WarrantsSilexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of $0.2603 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-298137). The gross proceeds to the Company from the exercise of the warrants are expected to be $837,366.36, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about September 29, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.
- BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in CologneBIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne
- Nasus Pharma, Ltd.Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of OndansetronTopline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026
- Dianthus Therapeutics, Inc. NEW YORK andDianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual MeetingDianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place September 29 to October 2, 2026 in Orlando, Florida.
- Keros Therapeutics to Receive Additional Development Milestone Payment from Partner TakedaCompanies: Takeda Pharmaceutical CompanyKeros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (“MF”) and anemia on concurrent ruxolitinib therapy.
- Zai Lab LimitedZai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)SHANGHAI & CAMBRIDGE, Mass., September 29, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026, in Madrid.
- Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes– KO-7246 regenerated functional β-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –
- After Historic FDA Hearing On Psychedelic Therapies, Grassroots Student Group Mobilizes To Shape What Comes NextSeptember 29, 2026 – WASHINGTON, D.C. — On September 14th, 2026 the U.S. Food and Drug Administration (FDA) held a public hearing on “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs.” Two weeks later, the hearing is over – but the opportunity for the public to help shape the federal conversation is not. […]
- iRegene therapeuticsiRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the — iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering...
- Hengrui PharmaHengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties SHANGHAI, Sept. 29, 2026 -- Hengrui Pharma...